Drs. Loriot, Koshkin on Results From Cohort 1 of the THOR Study

Yohann Loriot, MD, PhD, Institute Gustave Roussy, and Vadim Koshkin, MD, University of California, San Francisco, summarize the latest data presented on cohort 1 of the THOR study, which compared erdafitinib and chemotherapy in patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations.

Видео Drs. Loriot, Koshkin on Results From Cohort 1 of the THOR Study канала GU Oncology Now